Uncategorized Archives - Vista Partners LLC

Dow and Russell 2000 Rip Higher on Softer Data: Housing, AI and Health Care Stocks Drive Wall Street’s Late-November Rally -( $GOOG $LLY $MCD $META $MTWO $OPEN $SER $SOAR Rise!)

by Vista Partners LLC 2 hours ago 49Views 0Likes

U.S. stocks extended their post‑shutdown relief rally on Tuesday, November 25, 2025, with investors leaning into the idea that the Fed could start easing before the New Year. The S&P 500 climbed roughly .91% to finish near 6,765.88, the Dow Jones Industrial…

Novartis Extends Its SMA Bet: FDA Approval of Itvisma Puts One-Time Gene Therapy in the Spotlight -( $NVS $IBB $XBI )

by Vista Partners LLC 4 hours ago 85Views 0Likes

Novartis (NVS) just secured one of those FDA approvals that makes Wall Street sit up straighter and actuaries reach for stronger coffee, as regulators cleared Itvisma, a one-time gene replacement therapy for spinal muscular atrophy (SMA) in patients two years and older,…

Amazon Bets $50 Billion on Data Centers to Power U.S. Government AI -( $AMZN $NVDA $SPY )

by Vista Partners LLC 1 day ago 96Views 0Likes

Amazon (AMZN) is teeing up a $50 billion bet that the best way to win Washington’s AI future is to own the real estate, the power, and the silicon underneath it. A new Beltway company town In a move that would make…

Inside Resident Futurist Cathie Wood’s ARK Strategy: Why She Bought Nvidia & CoreWeave & Why Nokia Could be Next – ( $ARKK $CRWV $NOK $NVDA )

by Vista Partners LLC 2 days ago 210Views 0Likes

Cathie Wood, Wall Street’s resident futurist and ARK Innovation ETF (ARKK) captain, has once again donned her risk-protective cape, reclaiming her position among Nvidia (NVDA) devotees by buying the dip with characteristic panache. On Thursday, as Wall Street’s mood swung faster than…

Recycling as a Resource: Inside EverMetal’s Bid to Turn Trash Into Treasure -( $MTWO $SOAR )

by Vista Partners LLC November 18, 2025 167Views 0Likes

For decades, recycling was the domain of earnest suburban homeowners and aluminum can loyalists. But now, amid geopolitical scrambles for lithium, nickel, and cobalt, the practice has graduated from hobby to high finance. In the latest episode of The Minerals Metals Initiative, Hugo…

Steve Ballmer’s Intuit Dome Unveiled: $2 Billion HQ Redefines Sports Arenas and Corporate Campuses -( $INTU $MSFT $SPY )

by Vista Partners LLC November 18, 2025 301Views 0Likes

Intuit’s (INTU) latest splash isn’t in fintech, but in construction—where the budget now garners more buzz than its balance sheet. Yes, the $2 billion figure making headlines isn’t another buyback authorization or a Silicon Valley campus remodel: It’s the sticker price for…

Modular Medical Gains IRB Green Light for Next-Gen Tubeless Insulin Delivery Device -( $MODD )

by Vista Partners LLC November 17, 2025 291Views 0Likes

Modular Medical (NASDAQ: MODD) is injecting fresh ambition into the world of diabetes care, touting Institutional Review Board (IRB) approval to deliver insulin with its Pivot™ tubeless patch pump to adult study participants just as the company pursues FDA clearance for commercial…

Opendoor Unveils Special Dividend as Shares Skyrocket: Real Estate Gets a Dose of Silicon Savvy -( $OPEN $SPY $QQQ )

by Vista Partners LLC November 16, 2025 236Views 0Likes

Opendoor Technologies Inc. (NASDAQ: OPEN), the online real estate platform that once made home flipping look like flipping pancakes, has now flipped its script to become an artificial intelligence-driven enterprise, sending its stock soaring nearly 24% ahead of a special dividend announcement.…

Merck Mixes Up Its Pipeline With Cidara $9.2B Acquisition—GeoVax Keeps Driving Towards Value in the Vaccine Lane -( $MRK $CDTX $GOVX $IBB )

by Vista Partners LLC November 15, 2025 267Views 0Likes

Merck (MRK), ever the discerning giant of Big Pharma, has decided to join the prophylactic party by acquiring Cidara Therapeutics (CDTX) for a headline-grabbing $9.2 billion—a move that whispers both “strategic pipeline expansion” and “Keytruda’s patent clock is ticking, folks.” In a…

Can Centessa’s $250M Equity Windfall Transform Sleep Disorder Treatments? -( $CNTA $IBB $XBI )

by Vista Partners LLC November 12, 2025 270Views 0Likes

Centessa Pharmaceuticals made waves in biotech finance this week by pricing its $250 million public offering at $21.50 per American Depositary Share (ADS)—a move that sent investors and industry watchers scrambling for their calculators and a fresh cup of clinical optimism. Raising…

Uncategorized

Your Guide To Staying Informed In The Markets